本文へ移動

研究所

Menu

ジェロサイエンス研究センター

ホーム > 研究所 > センター紹介 > ジェロサイエンス研究センター > 部門紹介 > 代謝・内分泌研究部

代謝・内分泌研究部

研究テーマ-1「糖尿病・肥満におけるサルコペニアの進展機序の解明と早期予知指標・予防戦略の開発」

背景・目的

　超高齢社会のわが国では生活習慣病、特に高齢者糖尿病の増加と伴にサルコペニア・フレイルの発症が急増しており、その対策は医学的･社会学的に最優先の課題となっています。疫学研究により、糖尿病はサルコペニアの危険因子であることが示されており、さらに加齢に伴うサルコペニアに内臓肥満が合併した「サルコペニア肥満」では心血管病（CVD）や死亡リスクの上昇が報告されています。しかし、その進展機序や有用なバイオマーカー、効果的な予防法・治療法は不明であり、診断基準等の妥当性についても再考の余地があります。そこで、我々は糖尿病・肥満におけるサルコペニアの進展機序解明と早期予知指標の同定、ならびに予防戦略の開発を目指した研究を推進しています。

研究概要

　我々はこれまで、構築済の独自コホート（糖尿病・肥満症、健診受診者）を基盤に、糖尿病や肥満におけるサルコペニアの病態解明や効果的なバイオマーカーや評価法に関する研究を行ってきました。特に、肥満者におけるサルコペニア診断では、腹部筋肉量に着目した新たなサルコペニア肥満の測定法や、ウエスト周囲径と筋質の複合指標が診断に有用であることを報告しています（PLoS One 2015; Endocrine 2022）。さらにインピーダンス法・Phase angle（PhA）を用いた筋質評価の有用性も示しました（J Cachexia Sarcopenia muscle 2022）。また、筋量を負に制御するマイオスタチン（Mstn）に着目し、血中Mstn濃度が高インスリン血症と有意に関連することを認め、肥満症では高インスリン血症とMstnの相互作用による悪循環がサルコペニア肥満の形成に繋がる可能性を臨床的に捉えました（Diabetes Res Clin Pract 2018、図）。加えて、2型糖尿病においては、糖尿病治療薬・SGLT2阻害薬がMstnの分泌を抑制し、骨格筋量の維持に寄与することを報告しました（J Diabetes Investig 2020）。

研究テーマ-2「TREM2に着目した糖尿病・肥満における認知症の早期予知指標・予防戦略の開発」

背景・目的

　超高齢社会の本邦では高齢者糖尿病の増加し、認知症･軽度認知障害（MCI）の発症も急増しています。糖尿病はアルツハイマー型（AD）と脳血管性（VaD）のいずれの認知症発症リスクも有意に高め、糖糖尿病の治療遵守や健康寿命にも悪影響を及ぼす為、その進展機序や予知因子の同定は喫緊の課題です。認知機能低下の進展には、高血糖、反復する低血糖、インスリン抵抗性、酸化ストレスなど、複数の要因の関与する一方、我々のAMED研究（2017年）における系統的レビューでは、認知症予防において効果的な治療法やバイオマーカーは未確立でした。そこで我々は、糖尿病・肥満における認知症の早期予知指標ならびに効果的な予防戦略の開発を目指し、研究を推進しています。

研究概要

　我々は、糖尿病･肥満マウス骨髄細胞のマイクロアレイ解析により、単球･ミクログリアに発現する細胞表面受容体･Triggering receptor expressed on myeloid cells 2（TREM2）遺伝子の発現亢進を見出しました。TREM2は脳内アミロイドβ（Aβ）除去に関与し、切断酵素ADAM10に切断され、可溶型TREM2（sTREM2）として血中に放出されます。我々は、国立病院機構多施設共同糖尿病・肥満症コホート研究において、血中sTREM2が糖尿病患者の認知機能低下と関連し、特に血糖管理不良な患者にて認知症リスク指標となることを認めました（Diabetes Metab 2019; Front Endocrinol 2022）。また、久山町一般住民において、血中sTREM2高値群では10年後の全認知症、AD、VaDの発症リスクが2～3倍に上昇することを認め、sTREM2が認知症の早期予知指標となり得ることを報告しました（Ann Neurol 2019、図）さらに、糖尿病・MCIコホートにおいて、糖尿病患者に特徴的な血中sTREM2とAβ42/40比、tau等の血中バイオマーカーの経時的変化を報告しました（Diabetes Res Clin Pract 2022）。加えて、認知症モデルマウスへの植物由来フラボノイド･タキシフォリン投与では、海馬のTREM2発現と脳内炎症の抑制を介した認知症改善効果を世界で初めて明らかにしました（Proc Natl Acad Sci U S A 2019）。

先頭へ戻る

2025年

欧文（原著）

  1. Ikeue K, Kato H, Tanaka M, Yamakage H, Kato S, Iwasa M, Oishi K, Yamamoto Y, Kanasaki M, Masuda I, Ishii K, Satoh-Asahara N. Phase angle is a potential novel early marker for sarcopenia and cognitive impairment in the general population. J Cachexia Sarcopenia Muscle, 2025;16:e13820.
  2. Shimizu H, Miyamoto J, Hisa K, Ohue-Kitano R, Takada H, Yamano M, Nishida A, Sasahara D, Masujima Y, Watanabe K, Nishikawa S, Takahashi S, Ikeda T, Nakajima Y, Yoshida N, Matsuzaki C, Kageyama T, Hayashi I, Matsuki A, Akashi R, Kitahama S, Ueyama M, Murakami T, Inuki S, Irie J, Satoh-Asahara N, Toju H, Mori H, Nakaoka S, Yamashita T, Toyoda A, Yamamoto K, Ohno H, Katayama T, Itoh H, Kimura I. Sucrose-preferring gut microbes prevent host obesity by producing exopolysaccharides. Nat Commun., 2025;16:1145.

和文（総説）

  1. 浅原 哲子、石川 実里．心血管薬物療法の最新エビデンス：肥満症の病態生理と心血管疾患予防・薬物療法肥満と痩せの問題．心血管薬物療法 2025, 印刷中．

  2. 加藤 久詞、浅原 哲子．日本におけるサルコペニア肥満の定義と診断基準．臨床栄養 2025;146:466-471．

2024年

欧文（原著）

  1. Inui T, Kawamura N, Kubo K, Yamakage H, Satoh-Asahara N, Ogawa Y, Katsuura G. Oral intake of degalactosylated whey protein increases peripheral blood telomere length in young and aged mice. Sci Rep., 2024;14:30859.
  2. Yamamoto Y, Ikeue K, Kanasaki M, Yamakage H, Oishi K, Mori T, Satoh-Asahara N, Masuda I, Ishii K. Association between subjective walking speed and metabolic diseases in individuals with obesity: a cross-sectional analysis. Sci Rep., 2024;14:28228.
  3. Ishihara Y, Kusakabe T, Yasoda A, Kitamura T, Nanba K, Tsuiki M, Satoh-Asahara N, Tagami T. Comparison of the utility of SARC-F, SARC-CalF, and calf circumference as screening tools for sarcopenia in patients with osteoporosis. PLoS One, 2024;19:e0310401.
  4. Ishii K, Ogawa W, Kimura Y, Kusakabe T, Miyazaki R, Sanada K, Satoh-Asahara N, Someya Y, Tamura Y, Ueki K, Wakabayashi H, Watanabe Y, Yamada M, Arai H. Diagnosis of Sarcopenic Obesity in Japan: Consensus Statement of the Japanese Working Group on Sarcopenic Obesity. Geriatr Gerontol Int., 2024;24:997-1000.
  5. Kishimoto A, Komiyama M, Wada H, Satoh-Asahara N, Yamakage H, Ajiro Y, Aoyama H, Katsuura Y, Imaizumi A, Hashimoto T, Sunagawa Y, Morimoto T, Kanai M, Kakeya H, Hasegawa K. Efficacy of highly bioavailable oral curcumin in asymptomatic or mild COVID-19 patients: a double-blind, randomized, placebo-controlled trial. J Health Popul Nutr., 2024;43:93.
  6. Bouchi R, Izumi K, Ishizuka N, Uemura Y, Ohtsu H, Miyo K, Tanaka S, Satoh-Asahara N, Hara K, Odawara M, Kusunoki Y, Koyama H, Onoue T, Arima H, Tsushita K, Watada H, Kadowaki T, Ueki K. Internet of things-based approach for glycemic control in people with type 2 diabetes: a randomized controlled trial. J Diabetes Investig., 2024;15:1287-1296.
  7. Kusakabe T, Ishihara Y, Kitamura T, Yasoda A, Nanba K, Tsuiki M, Satoh-Asahara N, Tagami T. Beneficial effects of romosozumab on bone mineral density and trabecular bone score assessed by dual-energy X-ray absorptiometry in a family with osteogenesis imperfecta. Osteoporos Int., 2024;35:1303-1304.
  8. Yamakage H, Jo T, Tanaka M, Kato S, Hasegawa K Masuda I, Matsuhisa M, Kotani K, Noda M,  Satoh-Asahara N. Five percent weight loss is a significant 1-year predictor and an optimal 5-year cut-off for reducing the number of obesity-related cardiovascular disease risk components: the Japan Obesity and Metabolic Syndrome Study. Front Endocrinol (Lausanne), 2024;15:1343153.
  9. Yamamoto Y, Ikeue K, Kanasaki M, Yamakage H, Satoh-Asahara N, Masuda I, Ishii K. Age-wise examination of the association of obesity based on body mass index and waist circumference with metabolic diseases in comprehensive health checkup participants. Obes Sci Pract., 2024;10:e746.
  10. Nanba K, Blinder A, Udager A, Hirokawa Y, Miura T, Okuno H, Moriyoshi K, Yamazaki Y, Sasano H, Yasoda A, Satoh-Asahara N, Rainey W, Tagami T. Double somatic mutations in CTNNB1 and GNA11 in an aldosterone-producing adenoma. Front Endocrinol (Lausanne), 2024;15:1286297.
  11. Manaka K, Kato S, Sakamoto R, Yamakage H, Uema T, Kawai S, Shibata M, Hiratsuka I, I Nakachi S, Onoue T, Tsuchiya T, Fukui M, Hashimoto K, Suzuki A, Makita N, Ogawa Y, Arima H, Satoh-Asahara N, Masuzaki H, Impact of coronavirus disease 2019 on medical practice in endocrine and metabolic diseases in Japan: a nationwide surveillance study conducted by the Japan Endocrine Society. Endocr J., 2024;71:499-514.
  12. Kato H, Iwashita K, Iwasa M, Kato S, Yamakage H, Suganami T, Tanaka M, Satoh-Asahara N. Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP–NLRP3 Axis. Cells, 2024;13:284.
  13. Tokuda H, Hori T, Mizutani D, Hioki T, Kojima K, Onuma T, Enomoto Y, Doi T, Matsushima-Nishiwaki R, Ogura S, Iida H, Iwama T, Sakurai T, Kozawa O. Inverse relationship between platelet Akt activity and hippocampal atrophy: A pilot case-control study in patients with diabetes mellitus. World J Clin Cases., 2024;12:302-313.
  14. Omura T, Inami A, Sugimoto T, Kawashima S, Sakurai T, Tokuda H. Tirzepatide and glycemic control metrics using continuous glucose monitoring in older patients with type 2 diabetes mellitus: An observational pilot study. Geriatrics., 2024;9:27.
  15. Kamihara T, Tabuchi M, Omura T, Suzuki Y, Aritake T, Hirashiki A, Kokubo M, Shimizu A. Evolution of a large language model for preoperative assessment based on the Japanese circulation society 2022 guidelines on perioperative cardiovascular assessment and management for non-cardiac surgery. Circ Rep., 2024;6:142-148.
  16. Tokuda H, Hori T, Onuma T, Enomoto Y, Doi T, Matsushima-Nishiwaki R, Yamaguchi S, Tanabe K, Omura T, Ogura S, Iwama T, Iida H, Kozawa O. Serotonin reuptake inhibitor suppresses the activation of human platelets by a combination of thrombopoietin and collagen through inhibition of Rac and Rho/Rho-kinase. Biomed Res., 2024;45:231-241.
  17. Sugimoto T, Sakurai T, Uchida K, Kuroda Y, Tokuda H, Omura T, Noguchi T, Komatsu A, Nakagawa T, Fujita K, Matsumoto N, Ono R, Crane P, Saito T.  Impact of type 2 diabetes mellitus and glycated hemoglobin levels within the recommended target range on mortality in older people with cognitive impairment receiving care at a memory clinic:NCGG-STORIES. Diabetes Care, 2024;47:864-872.
  18. Hioki T, Tachi J, Matsushima-Nishiwaki R, Iida H, Kozawa O, Tokuda H. Oncostatin M suppresses bone morphogenetic protein-4-induced osteoprotegerin synthesis in MC3T3-E1 osteoblast-like cells: p70 S6 kinase attenuation. Cell Biochem Funct., 2024;42:e4068.
  19. Kamihara T, Tanaka K, Omura T, Kaneko S, Hirashiki A, Kokubo M, Shimizu A. Exploratory bibliometric analysis and text mining to reveal research trends in cardiac aging. Aging Med., 2024;7:301-311.
  20. Kamihara T, Omura T. Does atrial fibrillation occur exclusively in the elderly? Clin Case Rep., 2024;12:e9175.
  21. Kuroyanagi G, Hioki T, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Gallein increases the fibroblast growth factor 2-elicited osteoprotegerin synthesis in osteoblasts. Biochim. Biophys. Acta Gen Subj., 2024;1868:130635.
  22. Sugimoto T, Saji N, Omura T, Tokuda H, Miura H, Kawashima S, Ando T, Nakamura A, Uchida K, Matsumoto N, Fujita K, Kuroda Y, Crane PK, Sakurai T. Cross-sectional association of continuous glucose monitoring-derived metrics with cerebral small vessel disease in older adults with type 2 diabetes. Diabetes Obes Metab., 2024;26:3318-3327.
  23. Kuroyanagi G, Hioki T, Matsushima-Nishiwaki R, Omura T, Kozawa O, Tokuda H. Gallein increases prostaglandin F2α-induced osteoprotegerin and IL-6 secretion in osteoblasts. Biomed Rep., 2024;21:147.
  24. Tanaka K, Okazaki H, Omura T, Kamihara T, Tokuda H. The potential role of ChatGPT in enhancing diabetes management for older patients. Geriatr Gerontol Int., 2024;24:816-817.
  25. Kamihara T, Kawano R, Kinoshita T, Omura T, Kaneko S, Hirashiki A, Kokubo M, Shimizu A. Differences in iron kinetics during cardiac load between patients with atrial fibrillation and those with sinus rhythm. Cardiology, 2024;149:580-689.
  26. Omura T, Inami A, Sugimoto T, Kawashima S, Sakurai T, Tokuda H. Identification of atypical hypoglycemia via continuous glucosemonitoring in a patient presenting with hot flashes. J Gen Fam Med., 2024;25:392-394.
  27. Hioki T, Kuroyanagi G, Matsushima-Nishiwaki R, Omura T, Kozawa O, Tokuda H. Gallein but not fluorescein enhances the PGD2-stimulated synthesis of osteoprotegerin and interleukin-6 in osteoblasts. Geriatr Gerontol Int., 2024;203:102639.
  28. Osuka Y, Kojima N, Daimaru K, Ono R, Sugie M, Omura T, Motokawa K, Ueda T, Maruo K, Aoyama T, Inoue S, Sasai H. Effects of Radio-Taiso on health-related quality of life in older adults eith frailty: a randomized controlled trial. J Epidemiol., 2024;34:467-476.
  29. Ono T, Watanabe N, Hayakawa K, Kainuma S, Yamada H, Waseda Y, Kanda Y, Fukuoka M, Tokuda H, Murakami H, Kuroyanagi G. Comparative outcomes of cemented versus cementless stems in bipolar hemiarthroplasty for femoral neck fractures. Medicine, 2024;103:e39946.
  30. Sugimoto T, Araki A, Fujita H, Fujita K, Honda K, Inagaki N, Ishida T, Kato J, Kishi M, Kishino Y, Kobayashi K, Kouyama K, Kuroda Y, Kuwahata S, Matsumoto N, Murakami T, Noma H, Ogino J, Ogura M, Ohishi M, Shimada H, Sugimoto K, Kakenaka T, Tamura Y, Tokuda H, Uchida K, Umegaki H, Sakurai T. Multidomain intervention trial for preventing cognitive decline among older adults with type 2 diabetes: J-MIND-Diabetes. J Prev Alz Dis., 2024;11:1604-1614.

和文（総説）

  1. 浅原 哲子、田中 将志、山陰 一、加藤 久詞、梅澤 努、土井 秀典．酸化ストレス関連疾患の発症・進展抑制におけるタキシフォリンの機能的意義と現代未病への有用性．未病と老化 2024;33:45-54．
  2. 加藤 さやか、浅原 哲子．特集：糖尿病・ゲノム・遺伝子「肥満および肥満治療抵抗性に関与するゲノム研究の現状」月刊糖尿病 #154, 2024;16:79-86．
  3. 浅原 哲子、石川 実里．特集：肥満と痩せの問題「二次性肥満の除外と肥満関連健康障害の評価のための検査」Medical Practice 2024;41:1826-1832．

  4. 岩佐 真代、浅原 哲子．肥満合併症予防を目指したチーム医療によるサスティナブルな肥満症治療 －肥満・メタボ専門外来の２２年の軌跡－．肥満研究 2024;30:83-87．

2023年

欧文

  1. Kusakabe T, Arai H, Yamamoto Y, Nakao K, Akamatsu Y, Ishihara Y, Tagami T, Yasoda A, Satoh-Asahara N. Cross-sectional association of skeletal muscle mass and strength with dietary habits and physical activity among first-year university students in Japan: Results from KEIJI-U study. Nutrition, 2023;118:112265.
  2. Wakabayashi D, Kato S, Tanaka M, Yamakage H, Kato H, Kusakabe T, Ozu N, Kasama S, Kasahara M, Satoh-Asahara N, The Japan Obesity Metabolic Syndrome Study (JOMS) Group. Novel pathological implications of serum uric acid with cardiovascular disease risk in obesity. Diabetes Res Clin Prac., 2023;205:110919.
  3. Ikeue K, Kusakabe T, Yamakage H, Ishii K, Satoh-Asahara N. A Body Shape Index is useful for BMI-independently identifying Japanese patients with obesity at high risk of cardiovascular disease. Nutr Metab Cardiovasc Dis., 2023;34:387-394.
  4. Uno-Eder K, Satoh-Asahara N, Hibiya M, Uno K, Uchino T, Morita1 K, Ishikawa T, Kaneko T, Yamakage H, Kitaoka Y, Sawa T, Tsukamoto K, Teramoto T. Understanding Impacts of COVID-19 Restrictions on Glycemic Control for Patients with Diabetes in Japan. J Diabetes Metab Disord., 2023;22:1.
  5. Kawai S, Yamakage H, Kotani K, Noda M, Satoh-Asahara N, Hashimoto K. Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy. Endocr J., 2023;70:1175-1186.
  6. Iwasa M, Kato H, Iwashita K, Yamakage H, Kato S, Saito S, Ihara M, Nishimura H, Kawamoto A, Suganami T, Tanaka M, Satoh-Asahara N. Taxifolin Suppresses Inflammatory Responses of High- Glucose-Stimulated Mouse Microglia by Attenuating the TXNIP–NLRP3 Axis. Nutrients, 2023;15:2738.
  7. Kitamura T, Ishihara Y, Kusakabe T, Tsuiki M, Nanba K, Hiroshima-Hamanaka K, Satoh-Asahara N, Yasoda A, Tagami T. A case of osteogenesis imperfecta caused by COL1A1 mutations, coexisting with pituitary stalk interruption syndrome. Endocr J., 2023;70:839-849.
  8. Inoue T, Fu B, Nishio M, Tanaka M, Kato H, Tanaka M, Itoh M, Yamakage H, Ochi K, Ito A, Shiraki Y, Saito S, Ihara M, Nishimura H, Kawamoto A, Inoue S, Saeki K, Enomoto A, Suganami T, Satoh-Asahara N. Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis. Nutrients, 2023;15:350.
  9. Iida H, Onuma T, Nakashima D, Mizutani D, Hori T, Ueda K, Hioki T, Kim W, Enomoto Y, Doi T, Matsushima-Nishiwaki R, Yamaguchi S, Tachi J, Tanabe K, Ogura S, Iwama T, Kozawa O, Tokuda H. Tramadol regulates the activation of human platelets via Rac but not Rho/Rho-kinase. PLoS One, 2023;18:e0279011.
  10. Sugimoto T, Tokuda H, Miura H, Kawashima S, Ando T, Kuroda Y, Matsumoto N, Fujita K, Uchida K, Kishino Y, Sakurai T. Cross-sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes. Diabetes Obes Metab., 2023;25:222-228.
  11. Nishikimi A, Nakagawa T, Fujiwara M, Watanabe K, Watanabe A, Komatsu A, Yasuoka M, Watanabe R, Naya M, Oshima H, Kitagawa Y, Tokuda H, Kondo I, Niida S, Sakurai T, Kojima M, Arai H. Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan. J Infect., 2023;86:e33-e35.
  12. Kuroyanagi G, Hioki T, Tachi J, Matsushima-Nishiwaki R, Iida H, Kozawa O, Tokuda H. Oncostatin M stimulates prostaglandin D2-induced osteoprotegerin and interleukin-6 synthesis in osteoblasts. Prostaglandins Leukot Essent Fatty Acids., 2023;192:102575.
  13. Hioki T, Kuroyanagi G, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Oncostatin M attenuates tumor necrosis factor-alfa-induced synthesis of macrophage-colony stimulating factor via suppression of Akt in osteoblasts. Connect Tissue Res., 2023;64:139-147.
  14. Li J, Nakagawa T, Kojima M, Nishikimi A, Tokuda H, Nishimura K, Umezawa J, Tanaka S, Inoue M, Ohmagari N, Yamaguchi K, Takeda K, Yamamoto S, Konishi M, Miyo K, Mizoue T. Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study. PLoS One, 2023;18:e0283658.
  15. Enomoto Y, Onuma T, Hori T, Tanabe K, Ueda K, Mizutani D, Doi T, Matsushima-Nishiwaki R, Ogura S, Iida H, Iwama T, Kozawa O, Tokuda H. Synergy by ristocetin and CXCL12 in human platelet activation: Divergent regulation by Rho/Rho kinase and Rac. Int J Mol Sci., 2023;24:9716.
  16. Kuroyanagi G, Hioki T, Tachi J, Matsushima-Nishiwaki R, Iida H, Tokuda H, Kozawa O. Resveratrol inhibits basic fibroblast growth factor-induced macrophage colony-stimulating factor synthesis via the PI3-kinase/Akt pathway in osteoblasts. Biosci Biotechnol Biochem., 2023;87:1462-1469.
  17. Sugimoto T, Tokuda H, Miura H, Kawashima S, Omura T, Ando T, Kuroda Y, Matsumoto N, Fujita K, Uchida K, Kishino Y, Sakurai T. Longitudinal association of continuous glucose monitoring-derived metrics with cognitive decline in older adults with type 2 diabetes: A 1-year prospective observational study. Diabetes Obes Metab., 2023;25:3831-3836.
  18. Kuroyanagi G, Hioki T, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. HSP70 inhibitor amplifies the bFGF‑induced release of IL‑6 in osteoblasts. Mol Med Rep., 2023;28:230.
  19. Hioki T, Tachi J, Ueda K, Matsushima-Nishiwaki R, Iida H, Kozawa O, Tokuda H. Oncostatin M enhances osteoprotegerin synthesis but reduces macrophage colony‑stimulating factor synthesis in bFGF‑stimulated osteoblast‑like cells. Exp Ther Med., 2023;27:34.
  20. Kawai Y, Watanabe Y, Omae Y, Miyahara R, Khor SS, Noiri E, Kitajima K, Shimanuki H, Gatanaga H, Hata K, Hattori K, Iida A, Ishibashi-Ueda H, Kaname T, Kanto T, Matsumura R, Miyo K, Noguchi M, Ozaki K, Sugiyama M, Takahashi A, Tokuda H, Tomita T, Umezawa A, Watanabe H, Yoshida S, Goto Y, Maruoka Y, Matsubara Y, Niida S, Mizokami M, Tokunaga K. Exploring the genetic diversity of the Japanese population: Insights from a large-scale whole genome sequencing analysis. PLoS Genet., 2023;19:e1010625.
  21. Omura T, Katsumi A, Kawashima S, Naya M, Tokuda H. Prolonged COVID-19 infection in a patient with complete remission from follicular lymphoma with hyperosmolar hyperglycemic syndrome. Geriatrics, 2023;8:110.

2022年以前の主要な発表論文

  1. Satoh-Asahara N, Yamakage H, Tanaka T, Kawasaki T, Matsuura S, Tatebe H, Akiguchi I, Tokuda T. Soluble TREM2 and Alzheimer-related biomarker trajectories in the blood of patients with diabetes based on their cognitive status. Diabetes Res Clin Pract., 2022;193:110121.
  2. Tanaka M, Yamakage H, Muranaka K, Yamada T, Araki R, Ogo A, Matoba M, Watanabe T, Saito M, Kurita S, Yonezawa K, Tanaka T, Suzuki M, Sawamura M, Matsumoto M, Nishimura M, Kusakabe T, Wada H, Hasegawa K, Kotani K, Noda M, Satoh-Asahara N. Higher serum soluble TREM2 as a potential indicative biomarker for cognitive impairment in inadequately controlled type 2 diabetes without obesity: the DOR-KyotoJ-1. Front Endocrinol., 2022;13: 880148.
  3. Ikeue K, Kusakabe T, Muranaka K, Yamakage H, Inoue T, Ishii K, Satoh-Asahara N. A combined index of waist circumference and muscle quality is associated with cardiovascular disease risk factor accumulation in Japanese obese patients: A cross-sectional study. Endocrine, 2022;77:30-40.
  4. Akamatsu Y, Kusakabe T, Arai H, Yamamoto Y, Nakao K, Ikeue K, Ishihara Y, Tagami T, Yasoda A, Ishii K, Satoh-Asahara N. Phase angle from bioelectrical impedance analysis is a useful indicator of muscle quality. J Cachexia Sarcopenia Muscle. 2022;13:180-189.
  5. Yamakage H, Konishi Y, Muranaka K, Hotta K, Yoshihiro Y, Morisaki H, Morisaki T, Satoh-Asahara N. Association of protein tyrosine phosphatase 1B (PTPN1) gene polymorphism with the effects of weight reduction therapy on body weight and glycolipid profiles in obese patients. J Diabetes Investig., 2021;12:1462-1470.
  6. Yamakage H, Tanaka M, Inoue T, Odori S, Kusakabe T, Satoh-Asahara N. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial. J Diabetes Investig., 2020;11:653-661.
  7. Inoue T, Saito S, Tanaka M, Yamakage H, Kusakabe T, Shimatsu A, Ihara M, Satoh-Asahara N. Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A., 2019;116:11031-11038.
  8. Tanaka M, Yamakage H, Masuda S, Inoue T, Ohue-Kitano R, Araki R, Matoba Y, Saito M, Nagaoka T, Yonezawa K, Tanaka T, Suzuki M, Sawamura M, Nishimura M, Odori S, Wada H, Kotani K, Kusakabe T, Shimatsu A, Hasegawa K, Satoh-Asahara N. Serum soluble TREM2 is a potential novel biomarker of cognitive impairment in Japanese non-obese patients with diabetes. Diabetes Metab., 2019;45:86-89.
  9. Ohara T, Hata J, Tanaka M, Honda T, Yamakage H, Yoshida D, Inoue T, Hirakawa Y, Kusakabe T, Shibata M, Teraoka T, Kitazono T, Kanba S, Satoh-Asahara N, Ninomiya T. Serum soluble TREM2 as a biomarker for incident dementia: the Hisayama study. Ann Neurol., 2019;85:47-58.
  10. Tanaka M, Honda T, Yamakage H, Hata J, Yoshida D, Hirakawa Y, Shibata M, Inoue T, Kusakabe T, Satoh-Asahara N, Ninomiya T. A potential novel pathological implication of serum soluble triggering receptor expressed on myeloid cell 2 in insulin resistance in a general Japanese population: The Hisayama study. Diabetes Res Clin Pract., 2018;146:225-232.
  11. Tanaka M, Masuda S, Yamakage H, Inoue T, Ohue-Kitano R, Yokota S, Kusakabe T, Wada H, Sanada K, Ishii K, Hasegawa K, Shimatsu A, Satoh-Asahara N. Role of serum myostatin in the association between hyperinsulinemia and muscle atrophy in Japanese obese patients. Diabetes Res Clin Pract., 2018;42:195-202.
  12. Tanaka M, Matsuo Y, Yamakage H, Masuda S, Terada Y, Muranaka K, Wada H, Hasegawa K, Shimatsu A, Satoh-Asahara N. Differential effects of GLP-1 receptor agonist on form cell formation in monocytes between non-obese and obese subjects. Metabolism, 2016;65:1-11.
  13. Matsuo Y, Tanaka M, Yamakage H, Sasaki Y, Muranaka K, Hata H, Ikai I, Shimatsu A, Inoue M, Chun TH, Satoh-Asahara N. Thrombospondin 1 as a novel biological marker of obesity and metabolic syndrome. Metabolism, 2015;64:1490-1499.
  14. Satoh-Asahara N, Kotani K, Yamakage H, Yamada T, Araki R, Okajima T, Adachi M, Oishi M, Shimatsu A, Japan obesity and metabolic syndrome study (JOMS) group. Cardio-ankle vascular index predicts for the incidence of cardiovascular events in obese patients: A multicenter prospective cohort study (Japan Obesity and Metabolic Syndrome study: JOMS). Atherosclerosis, 2015;242:461-468.
  15. Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism, 2013;62:347-351.
  16. Satoh-Asahara N, Shimatsu A, Sasaki Y, Nakaoka H, Himeno A, Tochiya M, Kono S, Takaya T, Ono K, Wada H, Suganami T, Hasegawa K, Ogawa Y. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care, 2012;35:2631-2639.
  17. Himeno A, Satoh-Asahara N, Usui T, Wada H, Tochiya M, Kono S, Yamada-Goto N, Katsuura G, Hasegawa K, Nakao K, Shimatsu A. Salivary cortisol levels are associated with outcomes of weight reduction therapy in obese Japanese patients. Metabolism, 2012;61:255-261.
  18. Satoh-Asahara N, Suganami T, Majima T, Kotani K, Kato Y, Araki R, Koyama K, Okajima T, Tanabe M, Oishi M, Himeno A, Kono S, Sugawara A, Hattori M, Ogawa Y, Shimatsu A, The Japan Obesity Metabolic Syndrome Study (JOMS) Group. Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome. Clin J Am Soc Nephrol., 2011;6:265-273.

先頭へ戻る

連絡先

採用情報・共同研究など

代謝・内分泌研究部は、糖尿病・肥満症における『老年症候群（サルコペニア・認知症）』や『脳心血管病』の進展因子や予知指標を解明し、効果的な予防戦略の確立を目指した臨床研究・基礎研究を推進しています。

現在、研究員（常勤）を公募中です。このリンクは別ウィンドウで開きます
興味を持たれた方はお気軽にご連絡ください。

アカデミア（大学・研究所）や企業との共同研究も積極的に推進しています。
まずはお気軽にご連絡をお願いいたします。

問い合わせ先

浅原哲子（Noriko Satoh-Asahara）MD, PhD

国立研究開発法人国立長寿医療研究センター
副院長（併任：代謝内科部長）
ジェロサイエンス研究センター長（併任：代謝内分泌研究部 部長）

〒474-8511 愛知県大府市森岡町7-430
TEL：0562-46-2311（代）

E-mail：asahara[a]negg.go.jp
※[a]を@に置き換えて下さい。